Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-2.58 Insider Own2.30% Shs Outstand333.47M Perf Week2.34%
Market Cap41.47B Forward P/E- EPS next Y- Insider Trans7.03% Shs Float325.91M Perf Month3.19%
Income-861.20M PEG- EPS next Q- Inst Own95.80% Short Float5.63% Perf Quarter-7.48%
Sales6.59B P/S6.30 EPS this Y-610.50% Inst Trans-3.08% Short Ratio5.74 Perf Half Y-7.90%
Book/sh15.20 P/B8.18 EPS next Y- ROA-3.30% Target Price52.38 Perf Year36.17%
Cash/sh1.73 P/C71.96 EPS next 5Y15.24% ROE-16.50% 52W Range90.92 - 153.10 Perf YTD5.93%
Dividend- P/FCF40.63 EPS past 5Y-33.00% ROI-0.10% 52W High-18.77% Beta0.95
Dividend %- Quick Ratio1.20 Sales past 5Y50.10% Gross Margin67.80% 52W Low36.78% ATR3.24
Employees17200 Current Ratio1.50 Sales Q/Q76.50% Oper. Margin11.50% RSI (14)51.61 Volatility3.30% 2.56%
OptionableYes Debt/Eq3.42 EPS Q/Q22.20% Profit Margin-13.10% Rel Volume0.46 Prev Close124.62
ShortableYes LT Debt/Eq3.37 EarningsMay 08 BMO Payout- Avg Volume3.20M Price124.36
Recom3.00 SMA200.66% SMA50-0.56% SMA200-0.17% Volume1,482,400 Change-0.21%
28-Feb-14Reiterated UBS Buy $141 → $170
28-Feb-14Reiterated RBC Capital Mkts Outperform $151 → $158
27-Feb-14Reiterated Aegis Capital Buy $160 → $180
08-Jan-14Reiterated UBS Buy $125 → $141
08-Jan-14Reiterated Ladenburg Thalmann Buy $123 → $155
08-Jan-14Reiterated FBR Capital Outperform $130 → $153
03-Dec-13Reiterated UBS Buy $115 → $125
01-Nov-13Reiterated Ladenburg Thalmann Buy $127 → $123
30-Oct-13Initiated FBR Capital Outperform $130
07-Oct-13Reiterated CRT Capital Buy $110 → $130
08-Aug-13Reiterated UBS Buy $96 → $115
07-Aug-13Reiterated Aegis Capital Buy $135 → $140
02-Jul-13Reiterated RBC Capital Mkts Outperform $76 → $100
10-Jun-13Upgrade CRT Capital Hold → Buy $100
29-May-13Reiterated Ladenburg Thalmann Buy $84 → $124
29-May-13Reiterated Deutsche Bank Buy $82 → $103
03-May-13Reiterated Deutsche Bank Buy $80 → $82
04-Apr-13Reiterated UBS Buy $83 → $81
04-Apr-13Reiterated RBC Capital Mkts Outperform $80 → $76
21-Mar-13Reiterated Deutsche Bank Buy $77 → $83
24-Jul-14 10:55PM  UCB's Brivaracetam Positive in Phase III Epilepsy Study Zacks
12:04PM  Botox Makers Bosses Put Money Where Their Mouths Are at New York Times
12:04PM  Allergans Bosses Put Money on Where Their Mouths Are at New York Times
10:17AM  Wall Street Junk Euphoria Backs Ackmans Allergan Dreams at Bloomberg
08:10AM  Valeant files official complaint about Allergan with Canadian regulator at MarketWatch
08:00AM  Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements PR Newswire
08:00AM  Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements CNW Group
23-Jul-14 06:10PM  Correction: Blog points out Valeant's diverse portfolio is key to its success at MarketWatch
06:06PM  Correcting an earlier blog post . at MarketWatch
03:02PM  Ominous Signs For Valeant In The Allergan Q2 Earnings Call at Seeking Alpha
09:38AM  Danger Zone: Stocks With Most Misleading Non-GAAP Earnings at Seeking Alpha
06:26AM  [$$] Allergan Leaves Investors Smiling at Barrons.com
22-Jul-14 04:33PM  BTIG: Valeant Must Sweeten Allergan Bid To More Than $200/Share Benzinga
03:30PM  Allergan, a Valeant Takeover Target, Plans 1,500 Job Cuts Zacks
02:11PM  Allergan: Waiting for a Deal at Barrons.com
09:37AM  Allergan Reiterates Plan to Preempt Valeant Offer at TheStreet
07:27AM  Allergan stand alone value now above Valeant offer, says Bernstein at theflyonthewall.com
06:39AM  Cramer's Mad Money - Go For GoPro (7/21/14) at Seeking Alpha
21-Jul-14 06:30PM  Allergan EPS Growth, Job Cuts Counter Valeant Investor's Business Daily
05:14PM  Allergan to cut 1,500 employees in restructuring AP
05:03PM  Ackman: Why I think Herbalife is going to collapse at CNBC
04:22PM  On The Fly: Closing Wrap at theflyonthewall.com
04:21PM  [video] Bill Ackman on Valeant Bid for Allergan; Herbalife at Bloomberg
04:21PM  Greenberg: Allergan's Dilemma at TheStreet
02:54PM  Ackman says not hedged in position in Allergan theflyonthewall.com
02:54PM  Botox Maker Plans Deep Job Cuts During Takeover Fight at BusinessWeek
02:22PM  What The SEC Should Ask Valeant; Allergan Investors Should Watch Out at Seeking Alpha
02:21PM  Allergan: Take That Valeant Pharmaceuticals! at Barrons.com
02:09PM  Allergan Stock Earnings: Good Enough to Fight off Valeant? at Motley Fool
01:53PM  Blog points out Valeant's diverse portfolio is key to its success at MarketWatch
01:45PM  Allergan to cut 1,500 employees in restructuring AP
01:44PM  Ackman: Why I think Herbalife is going to collapse at CNBC
01:09PM  Regional banks slip after BB&T setback at Financial Times
01:07PM  Regional banks slip after BB&T setback at Financial Times
01:02PM  3 Stocks Moving The Health Care Sector Upward at TheStreet
12:37PM  Video: Allergan Earnings Growth, Job Cuts Counter Valeant at Investor's Business Daily
12:37PM  Allergan Earnings Growth, Job Cuts Counter Valeant at Investor's Business Daily
12:35PM  [video] Allergan Plays Defense Against Valeant at Bloomberg
12:31PM  [video] Ackman: Will not raise offer for Allergan at CNBC
12:30PM  [video] Big pharma battle escalates at CNBC
12:10PM  On The Fly: Midday Wrap at theflyonthewall.com
11:48AM  Allergan's Best Defense: Delay, Delay, Delay at The Wall Street Journal
11:35AM  Allergan results turn up the heat on Valeant at MarketWatch
11:29AM  Allergan Earnings Growth, Job Cuts Counter Valeant at Investor's Business Daily
11:26AM  [video] Allergan's Largest Shareholder Sells Most of Holdings at MarketWatch
11:16AM  Allergan Beats on Q2 Earnings, Ups View & Plans 13% Job Cut Zacks
11:15AM  Allergan's Best Defense: Delay, Delay, Delay at The Wall Street Journal
11:04AM  Today's Market: Big Names Making Big Waves at Seeking Alpha
10:55AM  Trade-Ideas: Valeant Pharmaceuticals International (VRX) Is Today's "Storm The Castle" Stock at TheStreet
10:23AM  Allergan to cut 1,500 jobs as it fights Valeant takeover bid at Financial Times
09:48AM  Allergan to cut 1,500 employees in restructuring AP
09:45AM  Allergan Chops 1,500 Jobs to Fend Off Valeant at 24/7 Wall St.
09:44AM  [video] Faber Report: Allergan vs. Valeant at CNBC
09:10AM  [video] Elliott pushes to break up EMC at CNBC
09:08AM  Mondays Top Biotech Stories: Allergan, Anacor, and Sinovac Biotech at Motley Fool
08:53AM  [video] Cramer's stocks to watch: AGN & VRX at CNBC
08:44AM  Allergan to cut 1,500 employees in restructuring AP
08:39AM  Valeant Complains To SEC About Allergan's War Of Words at Forbes
08:30AM  Valeant Ratchets Up War With Allergan 24/7 Wall St.
08:30AM  Valeant Offer Weaker After Allergan Earnings 24/7 Wall St.
08:24AM  Allergan beats profit, sales estimates, to cut 1,500 jobs at MarketWatch
08:00AM  Early movers: GM, AGN, VRX, HAS, V, MA, IBM & more at CNBC
07:37AM  Valeant Complains to Regulators About Allergan at New York Times
07:37AM  In Takeover Bid, Valeant Complains to Regulators About Botox Maker at New York Times
07:28AM  Valeant accuses Allergan of making misleading statements at MarketWatch
07:13AM  Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements PR Newswire
07:13AM  Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements CNW Group
07:07AM  Valeant complains to regulators about Allergan at CNBC
07:05AM  [video] Valeant complains to SEC at CNBC
19-Jul-14 08:00AM  Can Anything Stop Drug Companies From Fleeing The U.S. Tax System? at Forbes
18-Jul-14 12:51PM  Key GOP senator signals readiness for inversion deal, The Hill says theflyonthewall.com
11:27AM  Samlyn undecided on support for Valeant bid for Allergan, Dow says at theflyonthewall.com
08:10AM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financ EDGAR Online
08:00AM  Valeant Pharmaceuticals Files Investor Presentation PR Newswire
08:00AM  Valeant Pharmaceuticals Files Investor Presentation CNW Group
17-Jul-14 10:46AM  Ackman Ties Valeant Drive to Buy Allergan to Easy Credit at Bloomberg
09:15AM  [video] Valeant, Allergan battle rages on at CNBC
08:00AM  Bausch + Lomb's VICTUS® Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Lens Fragmentation Procedure PR Newswire
08:00AM  Bausch + Lomb's VICTUS® Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Lens Fragmentation Procedure CNW Group
07:00AM  Paulson says Allergan could be wroth $220 per share, WSJ reports theflyonthewall.com
05:00AM  'Fast Money' Recap: What Does Carl Icahn Think? at TheStreet
16-Jul-14 05:44PM  John Paulson Talks Up Valeant and Allergan, and Merger Arb at 24/7 Wall St.
03:11PM  [video] Highlights from Delivering Alpha at CNBC
03:09PM  John Paulson: Allergan can't continue alone at MarketWatch
02:37PM  Paulson: No end to M&A activity in sight at CNBC
01:03PM  3 Stocks Advancing The Drugs Industry at TheStreet
10:36AM  Treasury calls on Congress to halt inversion deals at theflyonthewall.com
09:24AM  Why Is Wall Street Bullish on These 3 Stocks? at Motley Fool
09:20AM  Ackman rebukes Allergan over response to Valeant bid at MarketWatch
15-Jul-14 10:56AM  3 Soaring Stocks Courting Controversy at Motley Fool
14-Jul-14 09:32AM  Stocks to Watch: Citigroup, Riverbed, Abbvie at The Wall Street Journal
08:13AM  Allergan reiterates belief that Valeant model unsustainable in new presentation theflyonthewall.com
08:00AM  Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan PR Newswire
08:00AM  Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan CNW Group
13-Jul-14 11:31AM  Allergan: turnabout is fair play at Financial Times
11-Jul-14 04:48PM  Allergan comments on Pershing Squares definitive proxy solicitation theflyonthewall.com
02:25PM  Shire in talks with US drugmaker AbbVie over £30bn bid at Financial Times
01:38PM  Shire in talks with US drugmaker AbbVie over £30bn bid at Financial Times
02:16AM  Attention Investors: Don't Miss Out on This Trillion-Dollar Trend at Motley Fool
10-Jul-14 05:52PM  Allergan's Acquisition Target: It's Unclear at The Wall Street Journal
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Jun 23Option Exercise6.4510,20365,80934,202Jun 24 04:37 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Jun 23Sale121.7010,2031,241,67623,999Jun 24 04:37 PM
Mirovsky PavelPresident of Valeant EuropeJun 02Sale131.2510,0001,312,4860Jun 04 03:19 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.May 13Option Exercise6.4510,00064,50033,999May 14 04:29 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.May 13Sale130.0810,0001,300,83623,999May 14 04:29 PM
Provencio Norma AnnDirectorApr 01Sale132.185,000660,886137,495Apr 02 04:55 PM
Kornwasser LaizerEVP, Company Group ChairmanMar 21Buy134.972,481334,85953,582Mar 25 01:06 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Mar 17Option Exercise6.455,00032,25028,999Mar 19 04:33 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Mar 17Sale141.725,000708,60023,999Mar 19 04:33 PM
Weldon RyanEVP, Company Group ChairmanFeb 11Option Exercise0.0011,0000103,823Feb 12 04:43 PM
Stolz Brian M.EVP, Administration & CHCOFeb 11Option Exercise0.0014,700069,783Feb 12 04:08 PM
Schiller Howard BradleyEVP, CFOFeb 11Option Exercise0.0090,0000312,704Feb 12 03:51 PM
Kornwasser LaizerEVP, Company Group ChairmanFeb 11Option Exercise0.0045,000073,390Feb 12 03:34 PM
Provencio Norma AnnDirectorFeb 03Sale136.235,000681,158147,206Feb 04 06:15 PM
Weldon RyanEVP, Company Group ChairmanJan 24Option Exercise0.0019,0000101,539Jan 28 05:09 PM
Mirovsky PavelPresident of Valeant EuropeJan 24Option Exercise0.0010,000010,000Jan 28 05:00 PM
Kornwasser LaizerEVP, Company Group ChairmanJan 24Buy132.152,536335,12828,390Jan 28 04:51 PM
Stolz Brian M.EVP, Administration and CHCOJan 20Option Exercise0.0045,000077,939Jan 22 04:55 PM